October 21st 2024
Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the agent in consultation with the FDA.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Pembrolizumab Receives European Approval for Treatment of Urothelial Carcinoma
September 14th 2017Pembrolizumab has been approved by the European Commission for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.
Read More
Genomic Landscape of Prostate Cancer Aligns With Breast Cancer Subtypes
August 17th 2017An analysis of the genomic landscape of patients with prostate cancer shows that tumors separated into 3 clusters that aligned with the luminal A, luminal B, and basal subtypes found in breast cancer tumors, according to a presentation during the 2017 American Urological Association Annual Meeting.
Read More
Results from PART Feasibility Study Endorse Development of Full Trial
August 10th 2017Based on results of a feasibility study, researchers in the United Kingdom have decided to move forward with a full randomized controlled trial comparing partial prostate ablation (PA) with radical prostatectomy (RP) in patients with intermediate-risk prostate cancer, according to a presentation at the 2017 American Urological Association Annual Meeting.
Read More
Exploring the Combination of Epacadostat and Pembrolizumab in Urothelial Carcinoma
August 8th 2017Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology and director of genitourinary research at Fox Chase Cancer Center in Philadelphia, discusses the combination of epacadostat and pembrolizumab (Keytruda) for the treatment of patients with urothelial carcinoma.
Watch
Bladder Cancer Field Looking Toward Immunotherapy Combos to Improve Responses, Apolo Says
August 7th 2017Andrea Apolo, MD, discusses the pooled analysis of the phase Ib Javelin Solid Tumor study,<span style="font-size:10.8333px"> </span>and the phase I study of cabozantinib, nivolumab, and ipilimumab
Read More
Atezolizumab Moves to EU for Final Approval in Urothelial Carcinoma, NSCLC
July 24th 2017The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given its support on indications for atezolizumab (Tecentriq) in non–small cell lung cancer (NSCLC) and urothelial carcinoma.
Read More
Cross-Resistance to Docetaxel and Cabazitaxel in CRPC Mediated by ABCB1 Gene
July 20th 2017Results of an investigation presented at the 2017 American Urological Association Annual Meeting indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer (CRPC) is mediated by a common mechanism, overexpression of the ABCB1 gene.
Read More
Updated Results Confirm Frontline Pembrolizumab Benefit in Urothelial Carcinoma
July 7th 2017Updated phase II results from the KEYNOTE-052 trial showed that first-line treatment with pembrolizumab produced a long-lasting response for patients with cisplatin-ineligible advanced urothelial cancer.
Read More
Significance of KEYNOTE-045 Trial of Pembrolizumab vs Chemotherapy in Urothelial Carcinoma
June 22nd 2017Daniel P. Petrylak, MD, professor of Medicine and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the KEYNOTE-045 trial, a phase III open-label study of pembrolizumab (Keytruda) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial carcinoma.
Watch
Results for First-Line Pembrolizumab in Advanced Urothelial Carcinoma
June 21st 2017Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discusses biomarker findings and mature clinical results from KEYNOTE-052, which explored first-line pembrolizumab (Keytruda) in cisplatin-ineligible advanced urothelial carcinoma.
Watch
Split-Dose Gemcitabine and Cisplatin Well-Tolerated in Muscle-Invasive Bladder Cancer
June 15th 2017A study presented at the 2017 American Urological Association Annual Meeting demonstrated that a split-dose of gemcitabine and cisplatin as a neoadjuvant chemotherapy regimen for treating muscle-invasive bladder cancer has a good pathologic response with a high safety profile.
Read More
Avelumab/Axitinib Combo Shows Encouraging Activity in Frontline RCC
June 15th 2017The combination of the PD-L1 inhibitor avelumab with the VEGF inhibitor axitinib as a frontline regimen for advanced renal cell carcinoma induced a response rate of 58.2% in patients with advanced renal cell carcinoma.
Read More
Comparing Blue Light and White Light Cytoscopy in the Detection of Bladder Cancer
June 9th 2017Siamak Daneshmand, MD, associate professor of Urology, Director of Clinical Research, Keck School of Medicine of USC, discusses blue light cystoscopy compared with white light cystoscopy for patients with bladder cancer.
Watch
Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate Cancer
June 5th 2017Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Watch
Earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by nearly 40% for men with high-risk advanced or metastatic prostate cancer who were newly diagnosed or had not yet received hormone therapy in findings from 2 clinical trials presented at the 2017 ASCO Annual Meeting.
Read More
PFS Improved With Ramucirumab in Phase III Urothelial Carcinoma Trial
June 1st 2017The addition of ramucirumab to docetaxel led to a statistically significant improvement in progression-free survival versus docetaxel alone in previously treated patients with locally advanced or unresectable or metastatic urothelial carcinoma.
Read More
Exploring Active Surveillance in Younger Patients With Prostate Cancer
May 23rd 2017Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.
Watch